Alembic Pharmaceuticals Ltd Share Price (APLLTD)
Check the latest share price of Alembic Pharmaceuticals Ltd, along with the price target, peer comparison, quarterly results, recent news, expert analysis, shareholding pattern, and other key fundamentals to make informed investment decisions.
as on 04:01PM, 13 Jun 2025
NSE
Alembic Pharmaceuticals Ltd Stock Performance
Get live Alembic Pharmaceuticals Ltd share price, day's high and low, historical returns, and market stats.
Day's Low
Day's High
₹979.1Day's Price Range₹1,004.652 Week's Low
52 Week's High
₹725.252-Week Price Range₹1,303.9
| Returns % | |
| 1 Month Return | + 10.08 % |
| 3 Month Return | + 21.55 % |
| 1 Year Return | + 12.49 % |
| 3 Year Return | + 37.36 % |
| 5 Year Return | + 12.26 % |
| Market Stats | |
| Previous Close | ₹992.60 |
| Open | ₹986.70 |
| Volume | 47.03K |
| Upper Circuit | ₹1,191.10 |
| Lower Circuit | ₹794.10 |
Alembic Pharmaceuticals Ltd Fundamentals & Key Indicators
Check Alembic Pharmaceuticals Ltd market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
₹19,638.62 Cr
Return on Equity (ROE)
14.3
PE Ratio (TTM)
33.73
Return on capital employed (ROCE)
14.13
Industry PE ratio
57.39
Beta (LTM)
0.48
P/B Ratio
3.93
Dividend Yield
1.12
PEG Ratio
-19.06
Quarterly Earnings Growth YOY
-12.11
EPS (TTM)
31.33
Sector
Pharmaceuticals
Book Value
245.14
Technical Analysis
Bullish
View Technical Analysis
How to invest in Alembic Pharmaceuticals Ltd?
Investing in Alembic Pharmaceuticals Ltd is simple. You can open a free INDstocks investment account on the INDmoney App. Search for Alembic Pharmaceuticals Ltd or APLLTD on the app to check live prices of the stock and click on Buy or SIP. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.
For example: You can buy 10 shares of Alembic Pharmaceuticals Ltd or start an SIP based on the market price on each investment date.
You can easily transfer money to your stock account via the INDmoney app and start investing in stocks like Alembic Pharmaceuticals Ltd with just a few clicks!
Alembic Pharmaceuticals Ltd Stock's Interest Amongst Investors
Alembic Pharmaceuticals Ltd Valuation
Track how Alembic Pharmaceuticals Ltd P/E has moved over time to understand its valuation trends.
Alembic Pharmaceuticals Ltd in the last 5 years
Lowest (11.53x)
March 23, 2020
Today (33.73x)
June 13, 2025
Industry (57.39x)
June 13, 2025
Highest (53.41x)
January 3, 2023
Today’s Price to Earnings Ratio: 33.73x
Alembic Pharmaceuticals Ltd Stock Recommendation
Get updated buy, sell, and hold recommendations by analysts on Alembic Pharmaceuticals Ltd.
based on 11 analysts
63.64%
Buy
36.36%
Hold
0.00%
Sell
63.64% of analysts recommend a 'BUY' rating for Alembic Pharmaceuticals Ltd. Average target price of ₹1011
Source: S&P Global Market Intelligence
Alembic Pharmaceuticals Ltd Share Price Target
Get share price movements and forecasts by analysts on Alembic Pharmaceuticals Ltd.
Alembic Pharmaceuticals Ltd price forecast by 11 analysts
Upside of1.19%
High
₹1222
Target
₹1011.00
Low
₹885
Alembic Pharmaceuticals Ltd target price ₹1011, a slight upside of 1.19% compared to current price of ₹999.1. According to 11 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Alembic Pharmaceuticals Ltd revenue growth forecast
Expected growth rate Q1, FY2027:31.81%
Forecast
Actual
Including amortisation and stock based compensations
Alembic Pharmaceuticals Ltd EPS growth forecast
EPS estimate Q1, FY2027:48.29%
Forecast
Actual
Source: S&P Global Market Intelligence
Alembic Pharmaceuticals Ltd Financial Results
Get the annual and quarterly financial summary of Alembic Pharmaceuticals Ltd, including revenue, profit, loss and more.
Indices Featuring Alembic Pharmaceuticals Ltd Stock
Check stock indices that include Alembic Pharmaceuticals Ltd.
Alembic Pharmaceuticals Ltd Earnings and Dividends
View detailed summary of the earnings and dividend history of Alembic Pharmaceuticals Ltd.
Alembic Pharmaceuticals Ltd Earnings Results
Alembic Pharmaceuticals Ltd’s net profit fell -11.96% since last year same period to ₹156.89Cr in the Q4 2024-2025. On a quarterly growth basis, Alembic Pharmaceuticals Ltd has generated 13.34% jump in its net profits since last 3-months.
Read More about Earnings ResultsAlembic Pharmaceuticals Ltd Dividends May,2024
In the quarter ending March 2024, Alembic Pharmaceuticals Ltd has declared dividend of ₹11 - translating a dividend yield of 1.10%.
Read More about Dividends
Alembic Pharmaceuticals Ltd Shareholding Pattern
View the shareholding pattern breakup of promoters, FIIs, DIIs, and retail investors in Alembic Pharmaceuticals Ltd.
| Investors | Holdings % | Quarterly Trend | 3M change |
|---|---|---|---|
| Promoter Holdings | 69.67% | 0.00 | |
| Foreign Institutions | 3.94% | 0.00 | |
| Mutual Funds | 9.2% | 0.00 | |
| Retail Investors | 9.96% | 0.00 | |
| Others | 7.24% | 0.00 |
Alembic Pharmaceuticals Ltd vs Peers
Compare market cap, revenue, PE, and other key metrics of Alembic Pharmaceuticals Ltd with its industry peers.
Company | Analyst View | Market Cap(in ₹ Cr) | 5 Year CAGR | Debt to Asset Ratio | Net Profit(in ₹ Cr) | Yearly Revenue(in ₹ Cr) |
|---|---|---|---|---|---|---|
| BUY | 19,638.62 | 2.45% | 0.55 | 615 | 6,228 | |
| BUY | 14,157.69 | -4.54% | 0.52 | 413 | 2,013 | |
| BUY | 67,394.66 | 9.93% | 0.56 | 3,168 | 29,001 | |
| HOLD | 98,102.78 | 32.58% | 0.64 | 3,854 | 19,547 | |
| BUY | 66,969.38 | 19.17% | 0.53 | NA | NA |
Alembic Pharmaceuticals Ltd News & Key Events
Latest news and events in one place to help you make informed investing decisions in Alembic Pharmaceuticals Ltd.
Alembic Pharma Sets Record Date for Dividend - 11 Jun, 2025
Alembic Pharmaceuticals has fixed July 29, 2025, as the record date for a proposed Rs 11 final dividend per share, subject to AGM approval on August 5, 2025.Alembic Pharmaceuticals Faces USFDA Observations, Shares Decline - 02 Jun, 2025
Alembic Pharmaceuticals' shares dropped nearly 2% following the USFDA's issuance of Form 483 with four observations after an inspection. Management believes the issues are addressable and will respond within the stipulated timeframe.Alembic Pharma Gains on USFDA Approval for Bosutinib - 30 May, 2025
Alembic Pharmaceuticals received USFDA approval for Bosutinib Tablets, used to treat chronic myelogenous leukemia, boosting shares by 2%. The drug targets a $291 million market.Alembic Pharma Secures USFDA Approval for New Drug - 23 May, 2025
Alembic Pharmaceuticals has received final USFDA approval for its Amlodipine and Atorvastatin Tablets, enhancing its product portfolio with a total of 223 ANDA approvals.Alembic Pharmaceuticals Secures USFDA Approval for Rivaroxaban - 15 May, 2025
Alembic Pharmaceuticals announced USFDA approval for Rivaroxaban Tablets in multiple strengths, with a market potential of $8,497 million. The 2.5 mg strength will launch in Q1 FY26.
Insights on Alembic Pharmaceuticals Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTRevenue Rich
Revenue is up for the last 5 quarters, 1.52K Cr → 1.78K Cr (in ₹), with an average increase of 3.9% per quarter
- POSITIVE IMPACT
Promoter Holding Up
Promoters have increased holdings from 69.61% to 69.67% in Mar 2025 quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, 138.42 Cr → 156.89 Cr (in ₹), with an average increase of 11.8% per quarter
- POSITIVE IMPACT
Price Rise
In the last 7 days, APLLTD stock has moved up by 0.9%
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 8.96% to 9.20% in Mar 2025 quarter
NO EFFECTAgainst Peers
In the last 1 year, Divis Laboratories Ltd has given 45.3% return, outperforming this stock by 32.8%
- NO EFFECT
Against Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 131.1% return, outperforming this stock by 93.7%
NEGATIVE IMPACTRetail Holding Down
Retail Investor have decreased holdings from 10.16% to 9.96% in Mar 2025 quarter
- NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 4.17% to 3.94% in Mar 2025 quarter
About Alembic Pharmaceuticals Ltd
Revenue: ₹1,769.64Cr as on March 2025 (Q4 FY25)
Net Profit: ₹156.63Cr as on March 2025 (Q4 FY25)
Listing date: 20 Sep, 2011
Chairperson Name: Chirayu R Amin
| Organisation | Alembic Pharmaceuticals Ltd |
| Headquarters | Vadodara |
| Industry | Pharmaceuticals |
| CEO | Chirayu R Amin |
| E-voting on shares | Click here to vote |
Mutual Funds that own Alembic Pharmaceuticals Ltd
Check out the Mutual Funds with significant holdings in Alembic Pharmaceuticals Ltd.
| Funds | Holdings | Prev. 5M |
|---|---|---|
| Kotak Small Cap Direct Growth | 2.01% | |
| DSP Midcap Fund Direct Plan Growth | 1.61% | |
| DSP Small Cap Fund Direct Plan Growth | 0.94% | |
| Axis Small Cap Fund Direct Growth | 0.54% | |
| DSP Healthcare Fund Direct Growth | 4.91% |
FAQs
What is Alembic Pharmaceuticals Ltd share price today?
Alembic Pharmaceuticals Ltd share price today stands at ₹999.1, Open: ₹986.7, Previous Close: ₹992.6, High: ₹1004.6, Low: ₹979.1, 52 Week High: ₹1303.9, 52 Week Low: ₹725.2.
What is today's traded volume of Alembic Pharmaceuticals Ltd?
Today's traded volume of Alembic Pharmaceuticals Ltd is 47.03K. Which means that 47.03K shares of Alembic Pharmaceuticals Ltd were bought and sold on the stock market during today's trading session.
What is Alembic Pharmaceuticals Ltd's market cap today?
Today's market capitalisation of Alembic Pharmaceuticals Ltd is ₹19,638.62 Cr. Market cap or market capitalisation is the total value of a company’s outstanding shares in the stock market, calculated by multiplying the current share price by the total number of shares issued by the company.
What is the 52 week high and 52 week low range of Alembic Pharmaceuticals Ltd?
Alembic Pharmaceuticals Ltd’s 52 week high is ₹1303.9 and 52 week low is ₹725.2. The current share price of Alembic Pharmaceuticals Ltd is ₹999.1, which is -23.38% down from its 52 week high and 37.77% up from its 52 week low.